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SHORT COMMUNICATION
Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in
Barrett's adenocarcinoma
A Swift', JM Risk', AN Kingsnorth2, TA Wright2, M Myskow3 and JK Field'
'Molecular Genetics and Oncology Group, Department ofClinical Dental Sciences and2Department ofSurgery, The University of
Liverpool, PO Box 147, Liverpool L69 3BX, UK; 3Department ofPathology, Broadgreen Hospital, Liverpool, UK.
Sary Alelic loss on chromosome 17 in 18 Barrett's oesophageal tumours was analysed with 17
polymorphic microsatellite markers. Loss of heterozygosity (LOH) of one or more markers was seen in 72%
(13 of 18) tumours on 17p and 56% (10 of 18) on 17q. The highest 17p losses were found at D17S799 (62%,
five of eight) and D17S261 (55%, five of nine), while loss at the p53 locus was 31% (5 of 16). The highest loss
on 17q was found at the TCF-2 (17q11.2-q12) locus with 66% (8 of 12) LOH. TCF-2 was the only marker
lost in two of the tumour samples; furthermore, TCF-2 was lost in four other tumours which retained
heterozygosity at the markers on either side of it, D17S261 and D17S740. Six markers were used to assess
LOH at 17q 1.2-q12, and five of eight of the tumour specimens which had LOH at TCF-2 had no other loss
on 17q. No statistically significant correlations were found between loss on 17q or 17p and any
clinicopathological parameters. We propose from these data that the 17qll.2-ql2 region contains a novel
predisposing gene in Barrett's adenocarcinomas and may represent the site of a tumour-suppressor gene.
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Barrett's columnar metaplasia of the squamous epithelium of
the oesophagus is a consequence of chronic gastro-
oesophageal reflux. It has been estimated that approxiimately
700 000 people in the United States have acquired Barrett's
oesophagus (Provenzale et al., 1994). The risk of developing
adenocarcinoma of the oesophagus in these patients is 30- to
40-fold higher than in the general population (Fennerty et
al., 1993; Stein and Stewart et al., 1993). Once diagnosed,
many patients with Barrett's oesophagus are entered into
surveillance programmes in order to detect histopathological
evidence of premalignant states, such as low-grade and high-
grade dysplasia. Oesophagectomy for those observed to have
early invasive carcinoma or high-grade dysplasia during such
surveillance programmes results in improved survival.
A clear sequence from low-grade dysplasia to high-grade
dysplasia to invasive carcinoma is observed to develop over a
substantial period of perhaps 3-5 years (Cameron and Lom-
boy, 1992). During the last two decades the incidence of
adenocarcinoma of the oesophagus has increased at a rate
exceeding that of any other cancer, with an incidence of 500
cancers per 100 000 patients with Barrett's metaplasia per
year (Haggitt, 1992).
Conventional histopathology with the detection of dys-
plasia is currently the only means of early diagnosis of
Barrett's cancers. Oesophageal cancers share a number of
molecular markers previously found in colorectal and gastric
cancers, especially loss of heterozygosity (LOH) in chromo-
somes 5 and 17 (Vogelstein et al., 1988; Leister et al., 1990;
Meltzer et al., 1991; Sano et al., 1991; Boynton et al., 1992;
Huang et al., 1992; Blount et al., 1993; Meltzer et al., 1994).
In addition, overexpression and mutations of the p53
tumour-suppressor gene are a frequent event in these
tumours (Baker et al., 1990; Hollstein et al., 1990; Huang et
al., 1993), and microsatellite instability has recently been
demonstrated in Barrett's cancers by Meltzer et al., (1994).
To date, the majority of investigations into LOH on
chromosome 17 in Barrett's cancers have concentrated on the
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region containing the p53 gene. We have undertaken a
detailed analysis of both chromosome 17 arms, using 17
microsatellite markers. The results of this investigation
indicate the highest loss of heterozygosity on the q arm of
chromosome 17 at 17qll.2-ql2.
Mateials and Methods
Specimens
Eighteen Barrett's oesophageal tumour specimens were col-
lected at the Royal Liverpool University Hospital, Depart-
ment of Surgery, and at the Cardiothoracic Centre, Liver-
pool. Tumour samples obtained from surgical specimens
were frozen in liquid nitrogen and stored at -70C. The
pathology of all these specimens was assessed by MM. The
sections were dissected to yield more than 50% tumour cells
for polymerase chain reaction (PCR) analysis.
DNA extraction
Genomic DNA was extracted from tumour specimens using
the Nucleon II DNA extraction kit (Scotlab) following the
manufacturer's instructions. Genomic DNA samples were
stored at 4C.
PCR and LOH analysis
Microsatellite repeat primers were obtained from Isogen (The
Netherlands). PCR reactions were performed in a 25jil reac-
tion volume and contained 200 ng of genomic DNA, 200gM
dNTP, 5 pmol each of forward and reverse primers, 0.5 units
of Taq polymerase (Advanced Biotechnologies) and 2.5#1 of
lOx buffer [670mM Tris-HCIpH8.5, 166mM ammonium
sulphate; 67 mM magnesium chloride; 1.7 mgml-' bovine
serum albumin (BSA); 100MM P-mercaptoethanol; 1% (w/v)
Triton X-100]. The reactions were denatured for 5 min at
95-C and then the DNA was amplified for 30 cycles of 95'C
for 30 s, 57C for 30 s and 72'C for 30 s. A I0ul volume of
the PCR product was electrophoresed for 10 h on a 10%
polyacrylamide gel at 250 V and viewed by silver staining.Chromosome 17 LOHl i Barr's aadinoarciano
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Results
We have undertaken a LOH study on 18 Barrett's
oesophageal tumours on chromosome 17, using 17 polymor-
phic microsatellite markers (Table I), in order to ascertain
common regions of deletions on both arms of this
chromosome and evaluate whether allelic loss was concent-
rated in any particular region. Loss of one or more markers
was seen in 72% (13 of 18) of the specimens on 17p and in
56% (10 of 18) on 17q.
Significantly high frequencies of LOH (ie. > 30%) on 17p
were found at D17S799 (63%, five of eight) and D17S261
(55%, five of nine), while loss of the p53 marker, TP53,
usually occurred with one or all of the three markers located
centromeric to it (D17S520, D17S799, CHRNBI), and was
the sole 17p locus lost in only one case (patient 3). The
highest loss on 17q was found to be at the TCF-2 locus, with
66% LOH (8 of 12). It is of note that the TCF-2 marker was
the only marker lost in two of the Barrett's oesophageal
tumours (patients 8 and 18). Furthermore, TCF-2 was lost in
four tumours which retained heterozygosity at informative
markers on either side of it.
We have used six markers in the 17qll.2-ql2 region as
assigned by linkage mapping and show that five of eight of
those Barrett's oesophageal tumours which have a loss at
TCF-2 have no other losses on 17q. Figure 1 demonstrates
Table I Loss of heterozygosity on chromosome
oesophageal tumours
17 in Barrett's
Loss/informative,
Map localisation Marker no. analysed Loss(%)
17pl3.3-ql I D17S578 2/8/16 25
17pl3.1 TP53 5/16/16 31
17pl3-pl2 D17S520 6/13j18 46
I7pl3.I-p12 D17S799 5//8/14 62
17pl2-pl 1.1 CHRNB1 6/13/18 46
17pI2-p11.2 D17S122 3/12 18 25
17pl2-pl 1.2 D17S261 519!14 55
17q11.2-q12 TCF2 8/ 12 18 66
17q D17S740 2 6/13 33
17q D17S783 0/9/14 0
17q D17S798 0/12/14 0
17ql1.2-ql2 D17S250 2/11,11 18
17qll.2-qI2 THRAI 2/8/11 25
17q21.32 GP3A 2/8/18 25
17q21.3 -q23 MPO 1/9/18 11
17q D17S940 0/4/13 0
17q23-q25 D17S515 0/13/18 0
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D17S578 - -
TP53 - -
D17S520 - X
D17S799 - -
CHRNB1 - a
D17S122 x -
D17S261 a xI
TCF2 - -
D17S740 XI xI
D17S783 a xI
D17S798 - -
D17S250 - -
THRAl - -
GP3A x -
MPO - X-L
D17S940 XI Ni
diagrammatically the region of minimal loss at the TCF-2
locus at 17qll.2-ql2. No correlation was found between
loss on 17p or 17q and any clinicopathological parameters or
survival (Table II). Also, no clinical correlations were found
between loss at the TCF-2 locus and any clinical parameters
or survival.
We have detected a high incidence of loss of heterozygosity
at the TCF-2 locus (17ql1.2-ql2) on the q arm of
chromosome 17. Loss at this site has not been previously
reported in any oesophageal tumours including Barrett's
adenocarcinoma. Blount et al. (1993) reported 17p deletions
in 12/13 (92%) Barrett's oesophageal tumour specimens,
while we have found 72% (13/18) LOH on the 17p arm. In
comparison, on 17q we now report 56% (10/18) LOH,
whereas there are no previous reports of LOH on 17q in
Barrett's adenocarcinoma. In none of these cases was the
entire 17q arm lost, whereas 56% had partial or interstitial
deletions on 17q. The nearest similar study is that of Mori et
al. (1994), who studied losses on 17q in squamous cell car-
cinomas of the oesophagus. Their investigation centred
around the BRCAJ region located telomeric to that in which
we are interested and the marker nearest to the TCF-2 locus
they used was C117-316 (17ql2-q21.l), which had a low
LOH frequency.
There have been a number of investigations of other
tumour types suggesting that there may be novel tumour-
suppressor genes on both 17p and 17q. Apart from the p53
gene, several groups have reported the presence of a further
gene at 17pl3.3 in breast cancer (Coles et al., 1990; Sato et
al., 1990; Thompson et al., 1990), a finding also seen in
ovarian tumours (Eccles et al., 1990; Tsao et al., 1991;
Foulkes et al., 1993). We have recently described the site of
another putative tumour-suppressor gene in head and neck
squamous cell carcinomas at CHRNBI (17pl2-pll.l)
(Adamson et al., 1994). Furthermore, a number of genes on
17q have previously been implicated in breast cancer, includ-
ing BRCAI, NM23 and prohibitin (Hall et al., 1990; Leone et
al., 1991; White et al., 1991; Futreal et al., 1994; Miki et al.,
1994). To this can be added the oncogene c-erbB-2 (17ql2),
which most likely acts by increasing copy number (Van de
Vijver et al., 1988). There are a number of possible candidate
genes which have been assigned to the 17qll.2-ql2 region,
and these include NFI (neurofibromin 1), CSF3 (colony-
stimulating factor 3), erbB-2 (epidermal growth factor) and
ITB4 (integrin 04).
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Frge 1 Schematic diagram of the microsatellite markers analysed on chromosome 17 and the patterns of losses for eight cases of
Barrett's adenocarcinoma. The markers are Listed in order according to the sex-averaged genetic map from the GDB (UK)
database. Minimal area of loss on 17q is shown.
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Table H Clinicopathological characteristics of the patients with Barrett's oesophageal tumours inves-
tigated in this study
Tumour
Length Survival LOHf at
ID no. Sex (mm) T Status N Status M Status Gradea (months) Fateb 17q
FOOl M 025 2 0 0 Moderate 20 Alive NSR L
F002 M 035 1 0 0 Good 19 Alive NSR L
F003 M 060 3 +VE 0 Poor 8 Dead rec L
F004 M 025 3 +VE 0 Moderate 10 Dead rec L
F005 M 065 3 +VE 0 Poor 5 Dead rec H
F006 F ND ND ND ND ND 8 Dead rec L
F007 M ND ND ND ND Moderate 7 Dead rec H
F008 M 025 3 +VE 0 Poor 15 Alive NSR L
F009 M ND 0 ND ND ND 58 Alive NSR H
FOIO M 100 3 ND ND Poor 3 Dead rec H
FOI M 025 1 0 0 Moderate 1 Op Death H
F012 M 050 3 +VE 0 Moderate 2 Dead rec H
F013 M 025 3 +VE 0 Poor 1 Dead rec L
F014 M 075 1 +VE 0 Moderate 25 Dead rec L
F016 F 045 3 +VE 0 Poor 4 Dead rec H
F017 M 035 3 +VE 1 Moderate 1 Op Death L
F018 M 050 3 +VE 0 Moderate 18 Alive NSR L
F019 M ND ND ND ND ND 5 Dead rec H
ND, No dataaGrade: histological differentiation ofadenocarcinomas (moderate, good, poor). bAlive NSR.
Alive, no sign ofrecurrence; Dead rec, dead with recurrence; Op death, post-operative complications; CH,
retention of heterozygosity; L, loss of heterozygosity.
The LOH data presented in this study suggest that the
TCF-2 locus may represent an important predisposing gene
in Barrett's adenocarcinomas and may indicate the site of a
novel tumour-suppressor gene. The importance of this
finding will have to await the analysis of a larger sample of
Barrett's tumours, especially when specimens containing both
Barrett's premalignant and malignant tissue are investigated
with these markers. Such information will further our
knowledge of the clonal ordering of allelic losses in Barrett's
cancers, in which it has recently been proposed that 17p
allelic losses occur before 5q allelic losses during neoplastic
development of this disease (Blount et al.. 1994).
Ack d
This study was supported by a grant from the Mersey Region Health
Authority. We thank Dr J Whittaker for advice and critical reading
of the manuscript.
Referesces
ADAMSON R, JONES AS AND FIELD JK_ (1994). Loss of
heterozygosity studies on chromosome 17 in head and neck
cancer using microsatetite markers. Oncogene, 9, 2077-2082.
BAKER SJ, PREISINGER AC, JESSUP JM et al. (1990). p53 mutations
occur in combination with 17p allelic deletions as late events in
colorectal tumorigenesis. Cancer Res, 50, 7717-7722.
BLOUNT PL, MELTZER SJ, YIN J, HUANG Y, KRASNA MJ AND
REID BRI (1993). Clonal ordering of 17p and Sq aUelic losses on
Barrett's dysplasia and adenocarcinoma. Proc. Natl Acad. Sci.
USA, 90, 3221-3225.
BOYNTON RF, BLOUNT PL. YIN J et al. (1992). Loss of
heterozygosity involving the APC and MCC genetic loci occurs in
the majority of human esophageal cancers. Proc. Nat Acad.
Sci.USA, 89, 3385-3388.
CAMERON AJ AND LOMBOY CTI (1992). Barrett's oesophagus-an
acquired non-progressive disorder. Gastroenterology, 103,
1241-1245.
COLES C, THOMPSON AM, ELDER PA et al. (1990). Evidence imp-
licating at least two genes on chromosome 17p in breast car-
cinogenesis. Lancet, 336, 761-763.
ECCLES DM, CRANSTON G, STEEL CM, NAKAMURA Y AND
LEONARD RCF. (1990). Alele loss on chromosome 17 in human
epithelial cancer. Oncogene, 5, 1599-1601.
FENNERTY MB, SAMPLINER RE AND GAREWAL HS. (1993). Bar-
rett's esophagus-cancer risk, biology and therapeutic manage-
ment. Aliment. Pharmacol. T7her., 7, 339-345.
FOULKES WD, BLACK DM, STAMP GWH, SOLOMON E AND
TROWSDALE J. (1993). Very frequent loss of heterozygosity
throughout chromosome 17 in sporadic ovarian carcinoma. Int.
J. Cancer, 54, 220-225.
FUTREAL PA, LIU QY, SHATTUCKEIDENS D et al. (1994). BRCA1
mutations in primary breast and ovarian carcinomas. Science,
266, 120-122.
HAGG1TT RC. (1992). Adenocarcinoma in Barrett's esophagus: a new
epidemic. Cancer, 72, 1155-1158.
HALL JM, LEE MK, NEWMAN B et al. (1990). Linkage ofearly onset
familial breast cancer to chromosome 17q21. Seience, 250,
1684-1689.
HOLLSTEIN MC. METCALF RA. WELSH JA. MONTESANC R AND
HARRIS CC. (1990). Frequent mutation of the p53 gene in human
esophageal cancer. Proc. Natl Acad. Sci. USA, 87, 9958-9961.
HUANG Y. BOYNTON RF. BLOUNT PL et al. (1992). Loss of
heterozygosity involves multiple tumour suppressor genes im
human esophageal cancers. Cancer Res, 52, 6525-6530.
HUANG Y, MELTZER SJ. YIN J et al. (1993). Altered mRNA and
unique mutational profiles of p53 and rb in human esophageal
carcinomas. Cancer Res, 53, 1889-1894.
LEISTER I, WEITH A. BRUDERLEIN S et al. (1990). Human colorec-
tal cancer, high frequency of deletions at chromosome lp35.
Cancer Res, 50, 7232-7235.
LEONE A, MCBRIDE OW, WESTON A et al. (1991). Somatic allelic
deletion of NM23 in human cancer. Cancer Res, 51, 2490-2493.
MELTZER SJ, YIN J. HUANG Y et al. (1991). Reduction to
homozygosity involving p53 in esophageal cancers demonstrated
by the polymerase chain reaction. Proc. Natl Acad. Sci.USA, 8,
4976-4980.
MELTZER SJ, YIN J, MANIN B et al. (1994). Microsatel}ite instability
occurs frequently and in both diploid and aneuploid cell popula-
tions of Barrett's-associated esophageal adenocarcinomas. Cancer
Res, 54, 3379-3382.
MIKI Y, SWENSEN J, SHATTUCKEIDENS D et al. (1994). A strong
candidate for the breast and ovarian-cancer susceptibility gene
BRCAI. Science, 266, 66-71.
MORI T, AOKI T, IIDA F et al. (1994). Frequent loss of heterozygosity
in the region including BRACI on chromosome 17q in squamous
cell carcinoma of the oesophagus. Cancer Res, 54, 1638-1640.
PROVENZALE D. KEMP JA, ARORA S. AND WONG JB. (1994). A
guide for surveillance of patients with Barrett's esophagus.
Gastroenterology, 89, 670-680.
SANO T, TSUIINO T, KAZUHIRO Y et al. (1991). Frequent loss of
heterozygosity on chromosomes lq, Sq, and 17p in human gastric
carcinomas. Cancer Res, 51, 2926-2931.
SATO T, TANIGAMI A, YAMAKAWA K et al. (1990) Allelotype of
breast cancer: cumulative alek losses promote tumour progres-
sion in primary breast cancer. Cancer Res, 50, 7184-7189.choniuosoe 171.0H4 Barm's _de.icvr-oma
A Swift et a
STIN HI. AND STEWART JR. (1993) Barrett's esophagus:
pathogenesis, epidemiology, functional abnormalities, malignant
degeneration and surgical manant. Dysphagia, 8, 276.
THOMPSON AM, STEEL CM, CHElTY U et al. (1990). p53 gene
mRNA expression and chromosome 17p alle loss in breast
cancer. Br. J. Cancer, 61, 74-78.
ThAO S-W, MOK C-H, OIKE K et al. (1991). Involvement of p53 gene
in the allelic deletion of chromosome 17p in human ovarian
tumours. Anticancer Res., 11, 1975-1982.
VAN DE VIIVER MJ, PETERSE I, MOOI Wi et al. (1988). Neu-
protein overexpression in breast cacear association with comedo-
type ductal carcinoma in situ and limited prognostic value. N.Eng
J.Med, 319, 1239-1245.
VOGELSTEIN B, FEARON ER, HAMILTON SR et al. (1988). Genetic
alterations in colorectal tumour development N.Eng J.Med, 319,
525-532.
WHITE JJ, LEADBEFrER DH, EDDY RL et al. (1991). Assignment of
the human prohibitin gene (PHB) to chromosome-17 and
identification of a DNA polymorphism. Genomics, 11, 228-230.